The ACTC1 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human renal cell adenocarcinoma line 786-O. This product provides a loss-of-function model for the ACTC1 gene, enabling investigation of cardiac alpha-actin function in an epithelial cancer background. The polyclonal population allows bulk analysis of gene disruption effects without single-cell clone isolation.
The 786-O cell line originates from a primary clear cell renal cell carcinoma and harbors a mutant VHL tumor suppressor, leading to constitutive activation of hypoxia-responsive pathways. As an established model of kidney cancer, 786-O retains epithelial morphology and is employed to study tumorigenesis, drug resistance, and cytoskeletal remodeling. Its genetic background renders it particularly useful for examining how mutations in cytoskeletal proteins intersect with oncogenic signaling.
ACTC1 encodes cardiac alpha-actin, the primary actin isoform of the sarcomere thin filament in cardiomyocytes. This protein polymerizes to form filamentous actin and interacts with sarcomere components such as TPM1, TNNT2, MYH6, and ACTN2 to facilitate contraction. Transcriptional control of ACTC1 is governed by cardiac transcription factors including GATA4, NKX2-5, MEF2C, SRF, and the YAP/TAZ?CTEAD complex. In non-muscle contexts, cardiac actin can influence cytoskeletal organization, cell motility, and mechanical sensing. Its knockout in 786-O cells is expected to perturb actin dynamics and downstream processes mediated by costamere and Z-disc proteins, offering insights into isoform-specific functions.
Disruption of ACTC1 in the VHL-mutant 786-O background creates a unique model to explore the role of a muscle-specific actin in cancer cell biology. While ACTC1 is predominantly studied in cardiac physiology, its expression in renal cancer cells may contribute to migration, invasion, or adhesion under certain conditions. This knockout system permits dissection of these non-canonical activities in a well-characterized genetic context, potentially revealing crosstalk between actin cytoskeleton regulation and hypoxia-driven pathways. The model thus supports both fundamental research on actin isoform biology and applied studies in oncopharmacology.
Researchers can employ these polyclonal knockout cells in a variety of assays, including western blotting and RT-qPCR to verify ACTC1 disruption, immunofluorescence to assess actin filament organization, and functional tests such as wound-healing, transwell invasion, and proliferation assays. The cells are also suitable for colony formation studies and drug sensitivity profiling, particularly in screens for compounds targeting the actin cytoskeleton. Additionally, they may be used to evaluate the impact of cardiomyopathy-linked ACTC1 mutations when combined with expression constructs. For further technical information, please contact Ascent Research.
